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Abstract
Despite its well-described safety and efficacy in the treatment of sickle cell anemia (SCA) in high-
income settings, hydroxyurea remains largely unavailable in sub-Saharan Africa, where more than 
75% of annual SCA births occur and many comorbidities exist. Realizing Effectiveness Across 
Continents with Hydroxyurea (REACH, ClinicalTrials.gov NCT01966731) is a prospective, Phase 
I/II open-label trial of hydroxyurea designed to evaluate the feasibility, safety, and benefits of 
hydroxyurea treatment for children with SCA in four sub-Saharan African countries. Following 
comprehensive training of local research teams, REACH was approved by local Ethics 
Committees and achieved full enrollment ahead of projections with 635 participants enrolled over 
a 30-month period, despite half of families living >12km from their clinical site. At enrollment, 
study participants (age 5.4±2.4 years) had substantial morbidity, including a history of vaso-
occlusive pain (98%), transfusion (68%), malaria (85%), and stroke (6%). Significant differences 
in laboratory characteristics were noted across sites, with lower hemoglobin concentrations 
(p<0.01) in Angola (7.2±1.0 g/dL) and the DRC (7.0±0.9 g/dL) compared to Kenya (7.4±1.1 g/dL) 
and Uganda (7.5±1.1 g/dL). Analysis of known genetic modifiers of SCA demonstrated a high 
frequency of α-thalassemia (58.4% with at least a single α-globin gene deletion) and G6PD 
deficiency (19.7% of males and 2.4% of females) across sites. The CAR β-globin haplotype was 
present in 99% of participants. The full enrollment to REACH confirms the feasibility of 
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conducting high-quality SCA research in Africa; this study will provide vital information to guide 
safe and effective dosing of hydroxyurea for children with SCA living in Africa.
Keywords
Sickle cell anemia; children; feasibility; hydroxyurea; Africa
INTRODUCTION
Sickle cell anemia (SCA) is an inherited hematological disorder that is associated with 
severe morbidity and early mortality,1 and represents a common yet overlooked global 
health problem with over 300,000 affected infants born each year.2 Approximately 75% of 
these infants are born in sub-Saharan Africa, where early diagnosis and life-saving 
treatments are essentially unavailable.3,4 Awareness of SCA appears to be slowly improving 
with screening programs demonstrating the burden and benefits of early diagnosis.6–10 As 
more children with SCA survive infancy following early and accurate diagnosis with better 
access to preventive care, their medical needs resulting from untreated SCA will further 
strain the limited healthcare resources of most African countries.
Hydroxyurea represents the only currently practical disease-modifying therapy for children 
with SCA living in Africa and is included on the WHO List of Essential Medicines for 
Children12 and for Adults,13 but remains largely unavailable for most persons with SCA 
living in the region. Although the benefits of hydroxyurea are well proven in high-income 
settings,14–21 there are virtually no data regarding the feasibility, dosing, or safety of 
hydroxyurea treatment in sub-Saharan Africa.3 Despite experiences demonstrating that the 
benefits of hydroxyurea are optimized when the dose is escalated to maximum tolerated 
dose (MTD),15,22 it is unclear if MTD is practical in low and middle income (LMIC) 
settings or whether lower doses may be the best option in clinical settings where resources 
for monitoring dosing and toxicity are limited.23–25
Realizing Effectiveness Across Continents with Hydroxyurea (REACH, ClinicalTrials.gov 
NCT01966731) is a prospective, phase I/II open-label dose escalation trial of hydroxyurea in 
four sub-Saharan African countries designed to evaluate the safety, dosing, feasibility, and 
benefits of hydroxyurea for children with SCA.26 An important objective of the study is to 
gather local evidence in African settings, such that dosing and laboratory monitoring 
guidelines can be developed to increase availability of and access to hydroxyurea for the 
hundreds of thousands of children who desperately need it. In addition to investigating 
practical clinical outcomes, REACH also aims to develop local research capacity within a 
strong collaborative international research network.3 We now report the successful full 
enrollment of the REACH trial, and provide descriptions of the baseline characteristics of 
this large and multi-national study population.
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METHODS
Study Overview
REACH is a prospective phase I/II open label trial of hydroxyurea therapy for young 
children (age 1–10 years at enrollment) at four sub-Saharan African clinical sites: Luanda, 
Angola (Site 1); Kinshasa, Democratic Republic of Congo (Site 2); Kilifi, Kenya (Site 3); 
and Mbale, Uganda (Site 4). The trial is approved by the Cincinnati Children’s Hospital 
Medical Center (CCHMC) Institutional Review Board and by the Ethics Committees, along 
with appropriate local and national oversight bodies, at all four clinical sites. The rationale 
and details of the study design have been previously published.26 REACH aimed to enroll 
150 participants per site, which gives 90% power in a Simon two-stage design to show the 
frequency of dose-limiting cytopenias (the primary safety endpoint) is less than 30% if the 
true rate is 20%. Patients were recruited locally and selected from the large clinical 
population at each site, at the discretion of the local lead investigators. Each site had 
substantially more eligible patients than the study could enroll, and therefore chose which 
patients to recruit. Inclusion/exclusion criteria were intentionally broad requiring only a 
diagnosis of sickle cell anemia and a lack of concurrent chronic diseases or severe 
malnutrition (z-score <−3). There was purposefully no specification in regard to the 
frequency or severity of SCA complications, allowing local site investigators the ability to 
select participants with the most need for hydroxyurea, including patients with the highest 
clinical severity or the highest socioeconomic need (i.e., those who could not afford 
hydroxyurea if purchased outside of the study). Three sites provided group education early 
in the study recruitment period about hydroxyurea treatment and the REACH study to garner 
interest among their patient population and subsequently, approached families on an 
individual basis as they were seen at the clinic or hospital with acute complications of SCA.
Upon enrollment, participants entered a 2-month screening period to confirm study 
treatment eligibility, document adherence to clinic visits, and provide pre-treatment 
laboratory data and clinical events. Three of the four sites agreed that nominal 
reimbursement for travel was beneficial, while one site (Site 1) determined that enrollment 
in the study and the receipt of hydroxyurea was sufficient reimbursement and that travel 
reimbursement might create additional advantages from the rest of their large patient 
population. Study participants then entered a hydroxyurea treatment phase at a fixed dose of 
20 mg/kg/day, which was maintained for six months before escalating to maximum tolerated 
dose (MTD) based on pre-specified laboratory criteria.26 The study, which is still ongoing, 
will continues to a common termination date, currently scheduled for four years from the 
time the first child initiated hydroxyurea treatment.26
Data Collection and Analysis
Data were entered locally at each site into the internet-based Research Electronic Data 
Capture (REDCapTM) system, using web-based case report forms and instructions in three 
languages (English for Kenya and Uganda, French for the DRC, and Portuguese for 
Angola). Baseline data collection for all enrolled participants included demographic 
characteristics, comprehensive clinical history and physical examination, immunization 
history, concomitant medications, and steady-state laboratory results. The clinical history 
McGann et al. Page 3
Am J Hematol. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
details were provided as self-report by the parent or from the available medical records at 
each clinical site. For each study participant, z-scores were calculated for height-for-age 
(HAZ), weight-for-height (WHZ), and weight-for-age (WAZ) using the WHO growth 
metrics.27 HAZ is a measure of chronic malnutrition with values <−2 defined as stunting; 
WHZ is a measure of acute malnutrition with values <−2 defined as wasting; and WAZ is a 
less specific measure with values <−2 defined as underweight. Z-scores <−3 identify 
children with severe malnutrition and HAZ or WHZ<−3 was an exclusion criteria for 
REACH. Most study data were captured on paper, with primary source documents uploaded 
into the REDCap system to allow ongoing remote study monitoring, which helped ensure 
high quality and accurate study data.
Standardized Laboratory Methods
Each REACH site used local laboratory equipment to perform basic study measurements. 
Automated complete (full) blood counts were performed using a Sysmex XT-2000i 
Hematology Analyser (Sites 1 and 3), Sysmex XN-1000 (Site 2) and Sysmex XS-1000i (Site 
4). Absolute reticulocyte counts were measured using Sysmex equipment at Sites 1–3 but 
calculated by microscopy with vital staining at Site 4. Quantitative measurement of fetal 
hemoglobin (%HbF) was performed locally or as a send-out test, using either capillary zone 
electrophoresis (Sebia Minicap Flex Piercing for Sites 1 and 4; Sebia Capillarys 2 for Site 2) 
or HPLC (BioRad D-10 at Site 3). Serum chemistries were measured using Biosystems A15 
Random Access Analyzer (Site 1), Roche Cobas C111 (Site 2), ILab Aries Chemistry 
Analyser (Site 3), or Humastar 200 (Site 4). At baseline, serum was collected and whole 
blood was spotted onto dried blood spots (FTA cards, GE Healthcare Bio-Sciences, 
Pittsburgh, PA) for future extraction of DNA. FTA cards and serum samples were stored at 
−20°C or −80°C until further analysis.
Genetic Modifiers
FTA cards were kept frozen until transport to CCHMC, where DNA-based studies were 
performed to (1) confirm the diagnosis of SCA; (2) identify concomitant G6PD deficiency; 
(3) document the presence of α-thalassemia trait; and (4) determine the β-globin haplotype. 
DNA was prepared from FTA cards using the InstaGene Matrix protocol (Bio-Rad, 
Hercules, CA) as previously described.28 Briefly, the diagnosis of SCA was determined 
using a customized TaqMan probe designed for the HbS (sickle, rs334) polymorphism. For 
the small number of samples that were not homozygous for βS, β-globin gene sequencing 
was performed to identify additional thalassemic mutations. The G6PD A− variant was 
identified using three commercially available TaqMan probe sets (Applied Biosystems 
Foster City, CA); G202A (rs1050829) distinguished A and B isoforms, A376G (rs1050828) 
identified the A− variant, and sex was determined using SRY_VIC, and ABCD1_CCHS0H-
FAM for Y- and X-chromosomes, respectively. For the detection of alpha-thalassemia trait, 
the 3.7 kb α-globin gene deletion (−α 3.7) was scored using a copy-number variant TaqMan 
assay with custom TaqMan probes as described.29 This assay allows the quantification of α-
globin genes with the following results: no gene deletions (αα/αα), 1 gene deletion (−α3.7/
αα), or 2 gene deletion (−α3.7/−α3.7). The β-globin haplotype was determined using a 
combination of TaqMan probes and restriction digestion patterns to identify the classical 
polymorphisms that distinguish the five common haplotypes.30,31 This method allowed for 
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the detection of the Central African Republic (CAR, also known as Bantu), Benin (BEN), 
Senegal (SEN), Cameroon (CAM), and Arab-Indian (ARAB) haplotypes.
Statistical Methods
Categorical and continuous data were summarized by frequency (percent) and mean 
(standard deviation), respectively. Differences in categorical variables between sites were 
assessed by the Chi-squared test when appropriate. In cases were the expected number for 
any cell was less than 5, a Fisher exact test was used in place of the Chi-squared test. 
Differences in continuous variables between sites were tested using one way ANOVA. All 
calculations were done in R (version 3.2.4).
RESULTS
Enrollment
With the goal of enrolling and screening enough children to treat 600 with hydroxyurea, 
REACH enrollment was brisk due to the large volume of patients at each clinical site, 
coupled with great interest among the families and staff. Enrollment commenced at each site 
after all required approvals were obtained and the study teams were fully assembled and 
trained. The timing of enrollment initiation differed across sites, due to variations in 
timelines for Ethics Committees and regulatory approval at each site and within each 
country. Site personnel consented approximately 2–3 new patients per week, which gave 
ample time to complete the screening and enrollment forms, as well as collect appropriate 
and timely samples for all required laboratory studies. Sites 2 and 3 were the first to begin 
enrollment, while Sites 1 and 4 started approximately 8 months later, with a total of 635 
participants enrolled between July 2014 and December 2016 (Supplementary Figure 1). 
There was an intentional pause in enrollment at each site after 60 participants were enrolled, 
as part of the two-staged study design, which is reflected in the stepped pattern of the 
enrollment curve. Almost all of the enrolled participants (n=606, 95.4%) completed 
screening and initiated hydroxyurea study treatment. A total of 29 enrolled participants did 
not complete screening including 10 screen failures, 3 elective withdrawals of consent by the 
family, 9 participants not adherent to visits during the screening period, 3 participants who 
moved out of the region or country, and 4 deaths (Figure 1). The reasons for the 10 screen 
failures included not meeting the age criteria for inclusion (n=4), hemoglobin 
electrophoresis confirming a diagnosis of HbAA (n=1) or HbAS (n=1), a positive HIV test 
(n=2), and low HAZ or WHZ <−3 documenting severe malnutrition (n=2). The 9 non-
adherent participants were removed from the study prior to starting hydroxyurea at the 
discretion of the local site lead investigators, due to concerns that they would not be able to 
attend the protocol-direct clinic visits reliably during the treatment phase of the study.
Demographics
Table 1 summarizes the demographics of the 606 study participants who completed 
screening and initiated hydroxyurea treatment. Their mean (SD) age at enrollment was 5.4 
(2.4) years and 46.7% of participants were <5.0 years of age. There was an equal split 
between males (51.2%) and females (48.8%), with no significant differences in age or sex 
across sites. Mild to moderate malnutrition was common at all sites, with a mean (SD) WHZ 
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= −0.7 (1.0), HAZ = −0.9 (1.1), and WAZ = −0.9 (1.0). However, significant differences in 
nutritional status were observed across the four clinical sites (Table 1); for example, there 
was poor growth at Site 1 and Site 3, but essentially normal growth among participants at 
Site 4. A majority of enrolled participants at Site 3 (107/151=71%) had WAZ and HAZ <−1, 
and 23% of participants at site 1 (35/150) met the clinical definition for wasting with WHZ 
<−2.
Travel Distance to Clinic
Many enrolled study participants lived far from the clinical sites, yet agreed to travel long 
distances on a regular basis to enroll and complete screening. The median distance from 
home to clinic was 12.1km (IQR 6.2–20.1) but with significant differences across the four 
sites. In general, the urban settings of Site 1 and Site 2 (median distance 10.7 and 6.9km, 
respectively) recruited patients living closer to clinic than the rural settings of Site 3 and Site 
4 (median distance 19.9 and 15.3km, respectively). Supplementary Figure 2 illustrates the 
home location for each study participant, in reference to the clinical site.
Past Medical History and Physical Examination
Almost all enrolled children reported previous vaso-occlusive pain (98%) and dactylitis 
(80%), while 6% of the patients had previous stroke (Supplementary Table 1). At the time of 
enrollment, >70% of study participants at each site reported a history of previous blood 
transfusion except at Site 3, where fewer children (46%) had a history of transfusion. 
Routine care at all sites included prophylactic penicillin for children <5 years of age and 
folic acid supplementation, though there were significant differences in malaria preventive 
measures. The reported use of bed nets was common (85%), but there were significant 
differences noted across sites with participants at Site 1 (69%) less likely to report use of bed 
nets compared to Site 2 (90%), Site 3 (80%), and Site 4 (99%). Routine malaria 
chemoprophylaxis was provided year round at two sites (proguanil once daily at Site 3 and 
chloroquine once weekly at Site 4). Overall immunization rates were high, although some 
families did not have full documentation of previous vaccinations. Routine vaccinations for 
most participants across sites included Streptococcus pneumoniae, Haemophilus influenzae 
type b, measles, diphtheria, tetanus, pertussis, hepatitis B, and BCG. On physical 
examination, many children (50%) had icterus while baseline palpable splenomegaly was 
recorded in 99 participants (16%). Six enrolled children reported a history of surgical 
splenectomy.
Laboratory Parameters
Table 2 summarizes the baseline laboratory characteristics for all 606 study participants who 
completed screening across the four clinical sites. The laboratory values were generally as 
expected for untreated children with SCA, but some significant between-site differences 
were noted. For example, the average hemoglobin concentration was significantly lower at 
Site 1 (7.2 g/dL) and Site 2 (7.0 g/dL), compared to Sites 3 (7.4 g/dL) and 4 (7.5 g/dL). 
Similarly, the baseline proportion of fetal hemoglobin was significantly higher at Site 4 than 
the other three clinical sites. There were additional small but significant differences in the 
baseline reticulocyte, leukocyte and neutrophil counts, and MCV (Table 2).
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Genetic Modifiers
Adequate DNA was extracted from all FTA cards transported to CCHMC for genetic testing 
(Table 3). Laboratory analysis confirmed the diagnosis of homozygous HbSS on the vast 
majority of samples, but 11 children (1.8%) had an unexpected diagnosis of HbS/β0 
thalassemia, including 1 from Site 1 and 10 from Site 3. Three null β-thalassemia mutations 
were identified by DNA sequencing. The most common mutation, found in 9 Kenyan 
children, was a G to T change at position 117 in exon 1 (rs33959855), which causes 
premature chain termination with Glu23Term. Two additional beta-null mutations included a 
24 base pair deletion in Intron 2 that includes the donor acceptor site for Exon 2 
(rs193922563) in one Kenyan child, and a C to T change at position 168 in Exon 2 
(rs193922563) in one Angolan child that causes premature termination with Gln40Term. All 
eleven children with HbS/β0 thalassemia had a low MCV (59.7±5.0 fL) and elevated HbA2 
(5.0±0.9%).
G6PD deficiency was common at all clinical sites, with the prevalence of affected 
hemizygous males ranging from 16–24% and heterozygous female carriers ranging from 
27–39% (Table 3). The B isoform was more common than the A isoform, with an allele 
frequency of 0.62. The normal A isoform and the pathologic A− isoform were both present 
with allele frequencies of 0.18 and 0.19, respectively. There was also a very high frequency 
of deletional α-thalassemia across sites, as defined by the presence of the African 3.7kb α-
globin gene deletion. Nearly half (290/606=48%) of enrolled participants had one α-globin 
gene deletion (−α3.7/αα), while 64 participants (11%) had two gene deletions (−α3.7/−α3.7) 
(Table 3). The presence of deletional α-thalassemia resulted in a significant incremental 
increase in hemoglobin concentration and absolute reticulocyte count (ARC), and a similar 
decrease in MCV for each gene deletion (Hb=7.1 g/dL, ARC=367 × 109/L, MCV=82 fL for 
αα/αα; Hb=7.3 g/dL, ARC=336 × 109/L, MCV=75 fL for −α3.7/αα; and Hb=7.7 g/dL, 
ARC=282 × 109/L, MCV=63 fL for (−α3.7/−α3.7, p<0.01). There was a trend toward lower 
HbF for participants without any α-globin gene deletions compared to those with one or two 
deletions, but this was not statistically significant (p=0.06). There were similar rates of α-
globin gene deletions among the 34 participants with previous stroke. Participants with two 
α-globin gene deletions were significantly less likely (p<0.01) to have previous blood 
transfusion (48%) than those with zero (70%) or one α-globin deletion (70%). There were 
no differences in the reported history of malaria across the α-globin genotypes. The β-globin 
haplotype was almost exclusively Central African Republic (CAR), with 92% of children 
having the homozygous CAR/CAR genotype; however, five children were identified with an 
Arab-Indian haplotype. Neither G6PD deficiency nor β-globin haplotype was associated 
with any significant differences in baseline laboratory values or reported clinical history.
DISCUSSION
The design of the REACH trial was ambitious, aiming to enroll and treat 600 children with 
SCA across four clinical sites in four different countries, with the goal of providing an 
accurate assessment of the safety and benefits of hydroxyurea in each clinical setting. Site 
readiness was initiated by a careful selection process based on interest and resources, 
followed by personnel training using web-based tools and training in three languages, plus 
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face-to-face interactions; these efforts culminated with formal site activation after all 
regulatory and logistical hurdles were cleared. Questions about the feasibility of enrolling a 
large number of children into a therapeutic trial in sub-Saharan Africa were voiced by 
several external review groups. However, the brisk enrollment rates quickly refuted those 
concerns, reflecting the careful training and dedication of the local clinical teams, as well as 
strong interest from families. Almost every family approached by the local team agreed to 
participate in the trial, reflecting the severity of SCA and the lack of available, affordable 
and effective treatment options for this life-threatening disease. Figure 1 illustrates that 
almost all enrolled study participants successfully completed screening and initiated 
hydroxyurea treatment, with <5% dropout across all four clinical sites. This degree of study 
retention is remarkable, especially when considering the effort required to attend the clinic 
for study visits, and the fact that many families have limited resources with challenging 
living conditions, multiple children, lack of reliable transportation, and long travel distances. 
Supplementary Figure 2 shows that 40% of participants traveled more than 15 km each way 
for study visits, often by various forms of connecting public transportation. Feasibility for 
the subsequent treatment phase will be assessed through recording the frequency of attended 
clinic visits within the protocol-specified study windows.
These pre-treatment REACH enrollment data allow comparisons among large cohorts of 
children with SCA across four countries in sub-Saharan Africa, with several important 
similarities and differences noted in their baseline laboratory values and clinical 
characteristics. Given the large population of patients at each site eligible to enroll in the 
REACH study, local investigators chose to approach patients with more clinically severe 
phenotypes. Each clinical site had many patients who might benefit from hydroxyurea, and 
local investigators had discretion to determine which patients were offered enrollment. 
Similar to the Phase I/II HUG-KIDS trial in the US, REACH offered treatment to those with 
the highest clinical severity to boost enrollment and adherence, while providing potential 
benefit to sicker children.32 The study purposefully provided relatively flexible inclusion and 
exclusion criteria, allowing local sites to determine which patients might benefit most from 
hydroxyurea therapy. This may have led to some selection bias that contributed to the 
differences in baseline characteristics among sites. Unsurprisingly, nearly all enrolled 
participants reported previous painful vaso-occlusive crises and malaria infection. The 
reported prevalence of each of these clinical diagnoses likely underestimates the actual 
value, however, given that this information was mostly obtained through parental self-report. 
Many diagnoses, such as acute chest syndrome, stroke, sepsis, and osteomyelitis require 
high clinical suspicion and advanced technology, which limits diagnostic accuracy in these 
resource-limited settings. Prophylactic treatment with penicillin were routinely prescribed at 
all sites and malaria chemoprophylaxis was prescribed at 2 of the 4 clinical sites, but 
adherence to these medications was not documented and may have been limited due to 
socioeconomic conditions. Most study participants also had received at least one blood 
transfusion, though Site 3 uses transfusions less frequently, due to decreased blood 
availability at this more rural site. As expected for untreated children with SCA living in low 
and middle-income countries, there was moderate malnutrition among most enrolled 
participants, with more wasting (lower WHZ) noted at Site 1 but more chronic malnutrition 
(lower HAZ) and underweight children (low WAZ) at Site 3. The causes of these differences 
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are not clear, but they may be important factors that influence the dosing, response, and 
toxicity of hydroxyurea therapy. It will also be important to carefully investigate how 
baseline nutritional differences contribute to these hydroxyurea parameters, and to monitor 
the effects of hydroxyurea therapy on these growth parameters over time.
Laboratory values revealed expected degrees of anemia and reticulocytosis, along with 
increased neutrophil and platelet counts. On average, however, the baseline hematological 
parameters demonstrated more severe anemia than age-matched patients in the US33 and 
Jamaica34, with a mean baseline hemoglobin concentration of 7.3 g/dL across the entire 
trial. These baseline hematological parameters were consistent with those previously 
described for other children with SCA in sub-Saharan Africa.35–37 There were several 
significant differences in baseline laboratory characteristics across sites (Table 2) that are 
possibly due to differences in the unique genetic, nutritional, and environmental 
backgrounds at each of the four locations. There were statistically significant differences 
noted in both bilirubin and ARC that could reflect important differences in baseline levels of 
hemolysis, which will require prospective evaluation to determine if these participants 
require or tolerate higher doses of hydroxyurea. Reflecting the CAR β-globin haplotype, 
average fetal hemoglobin levels were only 10–12% in these young cohorts (Table 2). This 
relatively low HbF starting point will allow prospective evaluation of the therapeutic benefits 
of hydroxyurea, both at the 15–20 mg/kg/day starting dose and after escalation to maximum 
tolerated dose in the subsequent treatment phase of the study.
Genetic analyses demonstrated the feasibility and utility of using dried bloodspots to isolate 
genomic DNA and perform several genotyping assays. Despite variation in local collection 
practices and storage conditions, DNA was successfully extracted from nearly all dried 
blood spot samples with evaluable results for all molecular assays performed. Despite a 
given diagnosis of homozygous HbSS for all participants, genetic analyses identified an 
unexpected diagnosis of HbS/β0-thalassemia for 11 REACH participants (1.8%), which has 
been rarely described in sub-Saharan Africa.38,39 The finding that eight children at Site 3 
carry the same null β-globin mutation suggests a founder effect, whose origin and migration 
patterns remain to be elucidated. This is a novel finding that deserves further investigation to 
determine the incidence of both HbS/β0-thalassemia and homozygous β-thalassemia major 
in East Africa. These findings are important and novel and demonstrate that β-thalassemia 
mutations indeed exist in both East and Central Africa, and that HbS/β0 or HbS/β+-
thalassemia should be considered for patients with elevated %HbA2 and decreased MCV. As 
previously described,40–42 there was a high frequency of both α–thalassemia and G6PD 
deficiency in our cohort, which may ameliorate the risk of severe malaria43–45 and sickle 
phenotype,46–52 but may also affect the responses to hydroxyurea therapy.53 Study 
participants with two α-globin gene deletions had significantly higher hemoglobin 
concentrations and were less likely to have been transfused prior to study entry, in 
comparison to those with one or zero α-globin gene deletions.
These baseline data from the REACH trial demonstrate important differences in the clinical 
and laboratory characteristics of children with SCA across Central and East Africa. The 
observed variability provides an important and unprecedented opportunity to prospectively 
evaluate the benefits, potential toxicity, and appropriate dosing of hydroxyurea within this 
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population. The current experience with hydroxyurea is limited mostly to high income 
countries where nutrition, antibiotics, and comprehensive care are the norm. Although the 
dosing, safety, and benefits of hydroxyurea have been clearly documented in high-income 
settings, it is not clear whether these clinical guidelines will be suitable or appropriate for 
lower income settings of sub-Saharan Africa. The REACH study has the opportunity to 
determine whether these differences in baseline nutritional, laboratory, genetic and clinical 
characteristics will influence the overall safety, benefits, or dosing of hydroxyurea therapy. 
However, while REACH includes a wide representation of patients across sub-Saharan 
Africa, our study population may not be representative of the entire African continent. 
Following the prospective evaluation of feasibility, safety, and dosing of hydroxyurea within 
REACH, it will be important to more widely evaluate the use of hydroxyurea in other 
clinical and geographical settings across sub-Saharan Africa, particularly in West Africa 
with additional variation in cultural, nutritional, socioeconomic, and genetic background.
Despite the overwhelming burden of disease, fewer than 0.1% of more than 250,000 
registered studies on ClinicalTrials.gov are focused on SCA and listed as either active or 
recruiting; as of November 2017, only 12 such studies are being conducted in Africa.54 
REACH is therefore a critically important research trial, representing the first and only 
multi-national study of hydroxyurea for patients with SCA living in sub-Saharan Africa. The 
successful enrollment and high-quality baseline data demonstrate an important step for SCA 
research within sub-Saharan Africa, and the study has the potential to provide robust, data-
driven guidelines for the optimal dosing and monitoring of hydroxyurea therapy. In addition, 
the REACH collaborative research network, fully trained and highly energetic, is now poised 
to address many additional unanswered questions about the clinical course, outcomes, and 
treatment options for children with SCA across sub-Saharan Africa.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. REACH Enrollment Consort Diagram
REACH aimed to enroll 150 children at each site with replacement of participants who did 
not complete three months of hydroxyurea treatment. This figure summarizes enrollment at 
each site, including those participants who did not complete the two-month screening 
period.
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